Daxor CEO to Present at H.C. Wainwright Global Investment Conference
ByAinvest
Wednesday, Sep 3, 2025 8:14 am ET2min read
DXR--
The presentation will be available on-demand starting Friday, September 5, at 7:00 a.m. ET, and investors can register for the conference here: [https://hcwevents.com/annualconference/](https://hcwevents.com/annualconference/) [1]. Feldschuh will also be available for one-on-one meetings with registered investors at the conference venue [1].
Daxor Corporation is tackling the "multi-billion-dollar silent crisis" in healthcare, which is the inability to precisely measure blood volume. This often leads to suboptimal care, prolonged hospital stays, and increased readmissions for high-cost medical conditions like heart failure and those requiring ICU care [1]. The company's patented, FDA-cleared Blood Volume Analysis (BVA) diagnostic offers real-time, precise data via a rapid, hand-held, lab-based system, empowering clinicians to make individualized treatment decisions [1].
The company's latest mid-year update highlights significant progress and milestones, including FDA clearance for its new rapid, lightweight BVA System and a 73 percent increase in unaudited revenues for the first half of 2025 compared to the same period in 2024 [3]. The new BVA system is three times faster and more portable than the existing BVA-100, offering improved fluid management capabilities [3].
Daxor's presentation at the H.C. Wainwright Conference provides an opportunity for investors to gain insights into the company's technological advancements, market adoption, and financial performance. Investors interested in one-on-one meetings with Feldschuh can contact Bret Shapiro at CORE IR either by calling 1-516-222-2560 or emailing brets@coreir.com [1].
References:
[1] Oak Ridge, TN, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today that CEO and President Michael Feldschuh will present at the H.C. Wainwright 27th Annual Global Investment Conference being held on September 8-10, 2025 in New York City at the Lotte New York Palace Hotel.
[2] Oak Ridge, TN, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today that CEO and President Michael Feldschuh will present at the H.C. Wainwright 27th Annual Global Investment Conference being held on September 8-10, 2025 in New York City at the Lotte New York Palace Hotel.
[3] Oak Ridge, TN, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today provides a mid-year corporate and financial update in a Letter to Shareholders from CEO and President Michael Feldschuh.
Daxor Corporation's CEO, Michael Feldschuh, will present at the H.C. Wainwright 27th Annual Global Investment Conference in New York City. The presentation will be available on-demand starting September 5, and Feldschuh will be available for one-on-one meetings with registered investors. Daxor is a global leader in blood volume measurement technology, aiming to address the "silent crisis" in healthcare of imprecise blood volume measurement.
Daxor Corporation (Nasdaq: DXR), a leading innovator in blood volume measurement technology, has announced that its CEO and President, Michael Feldschuh, will present at the H.C. Wainwright 27th Annual Global Investment Conference. The event will take place from September 8-10, 2025, in New York City at the Lotte New York Palace Hotel [1].The presentation will be available on-demand starting Friday, September 5, at 7:00 a.m. ET, and investors can register for the conference here: [https://hcwevents.com/annualconference/](https://hcwevents.com/annualconference/) [1]. Feldschuh will also be available for one-on-one meetings with registered investors at the conference venue [1].
Daxor Corporation is tackling the "multi-billion-dollar silent crisis" in healthcare, which is the inability to precisely measure blood volume. This often leads to suboptimal care, prolonged hospital stays, and increased readmissions for high-cost medical conditions like heart failure and those requiring ICU care [1]. The company's patented, FDA-cleared Blood Volume Analysis (BVA) diagnostic offers real-time, precise data via a rapid, hand-held, lab-based system, empowering clinicians to make individualized treatment decisions [1].
The company's latest mid-year update highlights significant progress and milestones, including FDA clearance for its new rapid, lightweight BVA System and a 73 percent increase in unaudited revenues for the first half of 2025 compared to the same period in 2024 [3]. The new BVA system is three times faster and more portable than the existing BVA-100, offering improved fluid management capabilities [3].
Daxor's presentation at the H.C. Wainwright Conference provides an opportunity for investors to gain insights into the company's technological advancements, market adoption, and financial performance. Investors interested in one-on-one meetings with Feldschuh can contact Bret Shapiro at CORE IR either by calling 1-516-222-2560 or emailing brets@coreir.com [1].
References:
[1] Oak Ridge, TN, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today that CEO and President Michael Feldschuh will present at the H.C. Wainwright 27th Annual Global Investment Conference being held on September 8-10, 2025 in New York City at the Lotte New York Palace Hotel.
[2] Oak Ridge, TN, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today that CEO and President Michael Feldschuh will present at the H.C. Wainwright 27th Annual Global Investment Conference being held on September 8-10, 2025 in New York City at the Lotte New York Palace Hotel.
[3] Oak Ridge, TN, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today provides a mid-year corporate and financial update in a Letter to Shareholders from CEO and President Michael Feldschuh.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet